Table 3:

Indications for and yield of testing by Ontario MOH* testing criteria

MOH testing criterionTest result; no. (%) of participants
n = 15 986
n = 2033
n = 1175
n = 11 437
Affected individuals
At least 1 case of cancer
 MOH1Ashkenazi Jewish and breast cancer before age 50 yr or ovarian cancer at any age43539 (9.0)24 (5.5)366 (84.1)
 MOH2Breast cancer before age 35 yr1036123 (11.9)108 (10.4)801 (77.3)
 MOH4Invasive serous ovarian cancer at any age1327195 (14.7)104 (7.8)1027 (77.4)
At least 2 cases of cancer on the same side of the family
 MOH5Breast cancer before age 60 yr and a first- or second-degree relative with ovarian cancer or male breast cancer1143147 (12.9)115 (10.1)880 (77.0)
 MOH6Breast and ovarian cancer in the same individual, or bilateral breast cancer with the first case before age 50 yr976127 (13.0)86 (8.8)763 (78.1)
 MOH7Two cases of breast cancer, both before age 50 yr, in first- or second-degree relatives1508134 (8.9)160 (10.6)1210 (80.2)
 MOH8Two cases of ovarian cancer, any age, in first- or second-degree relatives19552 (26.7)17 (8.7)122 (62.6)
 MOH9Ashkenazi Jewish and breast cancer at any age, and any family history of breast or ovarian cancer69138 (5.5)29 (4.2)621 (89.9)
At least 3 cases of cancer on the same side of the family
 MOH10Three or more cases of breast or ovarian cancer at any age5293355 (6.7)454 (8.6)4467 (84.4)
Unaffected individuals
MOH11Relative of individual with known BRCA1 or BRCA2 mutation2394860 (35.9)27 (1.1)237 (9.9)
MOH12Ashkenazi Jewish and first- or second-degree relative of individual with breast cancer before age 50 yr, or ovarian cancer at any age, or male breast cancer, or breast cancer at any age, with a positive family history of breast or ovarian cancer127792 (7.2)4 (0.3)1130 (88.5)
MOH13Pedigree strongly suggestive of hereditary breast or ovarian cancer (i.e., risk of carrying a mutation for the individual being tested is > 10%)210593 (4.4)175 (8.3)1830 (86.9)
  • Note: MOH = Ministry of Health, VUS = variant of uncertain significance.

  • * At the time of the study, responsibility for health lay with the provincial Ministry of Health and Long-Term Care; this ministry has since been divided into 2 separate ministries.

  • For any individual, multiple indications for testing could have been selected. The indication for testing was missing for 859 women. Criterion MOH3, for male breast cancer, is excluded from this table.

  • Percentages are calculated across each row, with the denominator for each row being the value in the column headed “All.”

  • § Of the 1341 women with a predictive negative result, 94.7% were tested under criterion MOH11; therefore, results are not shown for the predictive negative group.